Since CFL1 shows the strong ability to regulate sorafenib sensitivity, using NPs for systemic co‐delivery of sorafenib and siCFL1 could concurrently improve the accumulation of sorafenib in the HCC tumor tissues and enhance sorafenib sensitivity of HCC cells via silencing CFL1 expression. The gene discussed is CFL1; the disease is hepatocellular carcinoma.